5 months ago
OTLK
AnalystsJulian HarrisonJulian Harrison's Stock Forecasts
AnalystsJulian Harrison
Sectors:
Industries:
Analyst Ranking
Top 11%
#515 out of 4873 analysts
Average Return
+25.37%
Win Rate
45%20 out of 44
Risk vs Reward
Poor
Good
Julian Harrison's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Cymabay Therapeutics IncCBAY | +262.63% | $8.91 | $32.31 | 2023-03-09 - 2024-03-08 | Strong Buy |
Prometheus Biosciences IncRXDX | +233.20% | $60.00 | $199.92 | 2022-10-03 - 2023-06-15 | Strong Buy |
Cymabay Therapeutics IncCBAY | +212.31% | $10.40 | $32.48 | 2023-05-15 - 2024-03-21 | Strong Buy |
Cymabay Therapeutics IncCBAY | +199.91% | $10.83 | $32.48 | 2023-05-01 - 2024-03-21 | Strong Buy |
Cymabay Therapeutics IncCBAY | +193.67% | $11.06 | $32.48 | 2023-07-05 - 2024-03-21 | Strong Buy |
Julian Harrison Analyst Color
Get additional color on Julian Harrison's coverage of popular stocks
7 months ago
VRDN
8 months ago
VRDN
10 months ago
PTGX
a year ago
SYRE
2 years ago
CBAY
2 years ago
CBAY
2 years ago
CBAY
2 years ago
KROS
2 years ago
RXDX
3 years ago
RXDX
Julian Harrison's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Avalo Therapeutics IncAVTX | 1 | Strong Buy | $40.00 | +819.54% | Initiates Coverage On | 5 months ago |
Cartesian Therapeutics IncRNAC | 1 | Strong Buy | $42.00 | +303.07% | Initiates Coverage On | 5 months ago |
Outlook Therapeutics IncOTLK | 4 | Strong Buy | $9.00 | +525.00% | Maintains | 5 months ago |
Aclaris Therapeutics IncACRS | 3 | Strong Buy | $8.00 | +510.69% | Upgrades | 6 months ago |
Vyne Therapeutics IncVYNE | 1 | Strong Buy | $8.00 | +515.38% | Initiates Coverage On | 6 months ago |
Viridian Therapeutics IncVRDN | 3 | Strong Buy | $61.00 | +377.31% | Maintains | 7 months ago |
Rezolute IncRZLT | 2 | Strong Buy | $15.00 | +303.23% | Maintains | 8 months ago |
Liquidia CorpLQDA | 3 | Strong Buy | $25.00 | +62.87% | Maintains | 9 months ago |
Protagonist Therapeutics IncPTGX | 2 | Strong Buy | $51.00 | +16.12% | Maintains | 10 months ago |
Abivax SaABVX | 1 | Strong Buy | $43.00 | +527.74% | Initiates Coverage On | a year ago |
Spyre Therapeutics IncSYRE | 2 | Strong Buy | $40.00 | +211.04% | Maintains | a year ago |
Theravance Biopharma IncTBPH | 1 | Strong Buy | $21.00 | N/A | Initiates Coverage On | a year ago |
Anaptysbio IncANAB | 1 | Strong Buy | $55.00 | N/A | Initiates Coverage On | a year ago |
Apogee Therapeutics IncAPGE | 1 | Strong Buy | $43.00 | N/A | Initiates Coverage On | a year ago |
Akebia Therapeutics IncAKBA | 1 | Strong Buy | $4.00 | N/A | Assumes | a year ago |
Matinas Biopharma Holdings IncMTNB | 1 | Strong Buy | $150.00 | N/A | Reinstates | 2 years ago |
Cymabay Therapeutics IncCBAY | 7 | Strong Buy | $24.00 | N/A | Maintains | 2 years ago |
Moonlake ImmunotherapeuticsMLTX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Keros Therapeutics IncKROS | 2 | Strong Buy | $105.00 | N/A | Maintains | 2 years ago |
Prometheus Biosciences IncRXDX | 3 | Strong Buy | $181.00 | N/A | Maintains | 2 years ago |
Jade Biosciences IncJBIO | 3 | Strong Buy | $945.00 | N/A | Upgrades | 2 years ago |
Biora Therapeutics IncBIOR | 1 | Strong Buy | $4.00 | N/A | Assumes | 3 years ago |
United Therapeutics CorpUTHR | 1 | Hold | N/A | N/A | Initiates Coverage On | 3 years ago |
Morphic Holding IncMORF | 1 | Strong Buy | $64.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.